<DOC>
	<DOCNO>NCT01999673</DOCNO>
	<brief_summary>The primary purpose research study see whether add bavituximab ( investigational drug ) standard chemotherapy drug docetaxel , improve result treatment non-small-cell lung cancer .</brief_summary>
	<brief_title>Phase 3 Study Bavituximab Plus Docetaxel Versus Docetaxel Alone Patients With Late-stage Non-squamous Non-small-cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Key Male female least 18 year age Histologically cytologically confirm document stage IIIb/IV nonsquamous NSCLC accord American Joint Committee Cancer Staging Manual ( 7th Edition ) Radiographic disease recurrence progression frontline platinumbased doublet chemotherapy . For patient know epidermal growth factor receptor ( EGFR ) activate mutation anaplastic lymphoma kinase ( ALK ) translocation , appropriate target treatment use . Mutation test require . Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 Adequate hematologic , renal hepatic function Squamous , small cell , carcinoid , adenosquamous , largecell neuroendocrine , mixed histology contain smallcell squamouscell NSCLC Known history bleeding disorder , eg , von Willebrand disease hemophilia Cavitary tumor tumor invade abut large blood vessel Clinically significant bleeding gross hematuria , GI bleeding , hemoptysis within 6 month screen Thromboembolic event ( eg , deep vein thrombosis , pulmonary embolism , arterial thrombosis ) within 6 month screen Grade 2 high peripheral neuropathy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>SUNRISE</keyword>
	<keyword>PPHM 1202</keyword>
	<keyword>Bavituximab</keyword>
	<keyword>Peregrine</keyword>
</DOC>